Logo image
Back
Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study
Journal article   Open access

Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study

Zekui Fang, Xiping Wu, Li Xiao, Chunli Wang, Yanyan Zhao, Qingchao Zhang, Paola Anna Jablonska, Alonso La Rosa, Wolfram C M Dempke, Muhammad Furqan, …
Journal of thoracic disease, Vol.16(5), pp.3338-3349
05/31/2024
DOI: 10.21037/jtd-24-134
PMCID: PMC11170359
PMID: 38883659
url
https://doi.org/10.21037/jtd-24-134View
Published (Version of record) Open Access

Abstract

Background The significant progress has been made in targeted therapy for lung adenocarcinoma (LUAD) in the past decade. Only few targeted therapeutics have yet been approved for the treatment of lung squamous cell carcinoma (LUSC). Several higher frequency of gene alterations are identified as potentially actionable in LUSC. Our work aimed to explore the complex interplay of multiple genetic alterations and pathways contributing to the pathogenesis of LUSC, with a very low frequency of a single driver molecular alterations to develop more effective therapeutic strategies in the future.Methods We retrospectively analyzed the targeted next-generation sequencing (NGS) data (approximately 600 genes) of 335 patients initially diagnosed with non-small cell lung cancer (NSCLC) at our institution between January 2019 and March 2023 and explored the somatic genome alteration difference between LUSC and LUAD.ResultsWe analyzed that the presence of loss-of-function (LoF) mutations (nonsense, frameshift, and splice-site variants) in histone-lysine N-methyltransferase 2D (KMT2D) was much more prevalent in LUSC (11/53, 20.8%) than in LUAD (6/282, 2.1%). Moreover, our data indicated TP53 co-mutated with KMT2D LoF in 90.9% (10/11) LUSC and 33.3% (2/6) LUAD. Notably, the mutation allele fraction (MAF) of KMT2D was very similar to that of TP53 in the co-mutated cases. Genomic profiling of driver gene mutations of NSCLC showed that 81.8% (9/11) of the patients with LUSC with KMT2D LoF mutations had PIK3CA amplification and/or FGFR1 amplification.Conclusions Our results prompted that somatic LoF mutations of KMT2D occur frequently in LUSC, but are less frequent in LUAD and therefore may potentially contribute to the pathogenesis of LUSC. Concurrent TP53 mutations, FGFR1 amplification, and PIK3CA amplification are very common in LUSC cases with KMT2D LoF mutations. It needs more deeper investigation on the interplay of the genes and pathways and uses larger cohorts in the future.

Details

Metrics

4 Record Views
3 Times Cited - Web of Science
Logo image